trial

Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?

NCTId NCT01481883
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 13 (actual)
Sponsored by The Alfred
Primary completion 2019-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
13 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-01
Primary completion
2019-01
Eligibility
MALE · 18 Years · 45 Years

Interventions & indications

Drugs
Raloxifene Hydrochloride

Sponsors

The AlfredLead Sponsor

Investigators

1
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHDPrincipal Investigator

Sites

1 total
Melbourne, Australia

Facts & assertions

4 sourced
Enrollment
13
Phase
PHASE4
Primary Completion Date
2019-01
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene Hydrochloride
drug
lead_sponsor
The Alfred
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHD
person